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ABSTRACT: Current regulatory requirements impede clin-
ical translation and market introduction of many new
antimicrobial combination implants and devices, causing
unnecessary patient suﬀering, doctor frustration, and costs
to healthcare payers. Regulatory requirements of antimicrobial
combination implants and devices should be thoroughly
revisited and their approval allowed based on enrichment of
beneﬁt demonstrations from high-risk patient groups and
populations or device components to facilitate their clinical
translation. Biomaterial implant and devices equipped with
antimicrobial strategies and approved based on enrichment
claims should be mandatorily enrolled in global registry studies supervised by regulatory agencies for a minimum ﬁve-year
period or until statistically validated evidence for noninferiority or superiority of claims is demonstrated. With these
recommendations, this trans-Atlantic consortium of academicians and clinicians takes its responsibility to actively seek to relieve
the factors that stagnate downward clinical translation and availability of antimicrobial combination implants and devices.
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Improved dialogue between the various key players involved in the current translational blockade, which include patients,
academicians and doctors, policymakers, regulatory agencies, manufacturers, and healthcare payers, is urgently needed.
KEYWORDS: biomaterial-associated infection, downward clinical translation, prosthesis, enrichment, beneﬁt assessment,
risk assessment, biomaterials, surface modiﬁcation
■ CLINICAL NEED FOR ANTIMICROBIAL
COMBINATION DEVICES
Biomaterial implants and devices such as prosthetic joints and
other implants are used routinely to alleviate pain, ameliorate
function, and improve appearance to improve quality of life
and extend it. A major complication of these biomaterial
implants and devices is infection risk, occurring across nearly
all applications of biomaterials, whether internally implanted,
like total hip and knee arthroplasties,1,2 cardiovascular
electronic devices such as permanent pacemakers and
cardioverter deﬁbrillators3,4 and intraocular lenses,5 or
externally carried like contact lenses.6 On average, infection
rates may reach 5% across diﬀerent biomaterials applications.
Percutaneous devices, like bone ﬁxation pins and central
venous and urinary catheters, have infection rates much higher
than those of totally implantable devices, ranging up to several
tens of percentages,7 with the exception of dental implants that
resist infection better than most percutaneous implants.8
Regardless of the particular biomaterials implant or device in
question, biomaterials-related infections have caused dramatic
increases in patient morbidity and mortality9 and high ﬁnancial
burden to health care payers, including patients.10 A sobering
ﬁnding, for example, is that prosthetic joint infection places
patients at a mortality risk exceeding that of many cancers.11
■ REGULATORY LANDSCAPE: A BLOCKADE TO
DOWNWARD CLINICAL TRANSLATION
Numerous antimicrobial combination implants and devices are
reported annually in scientiﬁc publications. Most are based on
biomaterial (surface) modiﬁcations or (on-demand) drug-
releasing coatings to reduce microbial colonization.12 Many of
them have been primarily academically designed and are too
complex to be scaled and manufactured in a commercially
feasible scenario. In addition, their complexity makes it diﬃcult
to comply with the requirements deﬁned by national
policymakers and regulatory agencies. Although the United
States Food and Drug Administration (US FDA) and the
European Union (EU) have a similar focus to expedite
approval and clearance of safe and eﬀective medical
biomaterial implants and devices to the market, combination
devices still present a challenge13 with no united approach to
adoption. Combinational device approach is becoming even
more important since the recent issue of the new Europe’s
Medical Device Regulation (MDR) 2017/745,14 in which
notiﬁed body consultation with medicines authority is required
for devices whose substance or metabolites are systemically
absorbed to achieve intended action. A combination device
that incorporates medicinal substances always fell under the
old European Communities authorization rule, regardless of
the concentration of the substance, but combination devices
that previously fell below a minimum medicinal threshold
under MDR 2001/83/EC will now also be classiﬁed as
combination products. This elevates the challenges to obtain
regulatory approval and clearance for combination implants
and devices. Although the overall impact of this new MDR
remains to be seen, it may well yield higher risks and higher
costs, reducing innovation incentives for antimicrobial
technologies and their market introduction.
US FDA requires demonstration of both human beneﬁt and
assessment of risk prior to introducing new antimicrobial
combination implants and devices to the market, while the
European Union’s focus is on risk assessment. Regulatory
agencies struggle to deﬁne requirements for human beneﬁt and
risk assessment. Both industry and academia realize that
designing and conducting expensive clinical trials adequately
addressing regulatory requirements often have ambiguous
performance end points that are impossible to reach with
statistical conﬁdence with only 1−5 implant recipients in 100
developing serious infection that requires additional surgery or
treatment.15 This clearly hampers commercial feasibility.16,17
Moreover, end points of in vitro or animal studies (to the
extend that they are predictable for human clinical outcome)
are frequently expressed in terms of limiting microbial
colonization or infectious bioﬁlm formation, bioﬁlm removal
and degradation, inhibition of microbial colonization eﬀects on
bioﬁlm growth rate, and other fairly imprecise terminology that
does not address potential human beneﬁts in terms of reduced
infection rates. This, in the current regulatory landscape, causes
regulatory agencies to struggle with the risk/beneﬁt
proﬁle18−20 and leaves potential industrial partners interested
in bringing novel antimicrobial combination implants and
devices into clinical use in the dark with respect to ﬁnancial
returns in the marketplace.21
The few commercially available implants and devices
equipped with antimicrobial strategies, such as the CE-
approved gentamicin-releasing coating on intramedullary
nails, have been brought to the market at extreme costs,
which have been spent primarily to meet regulatory require-
ments.22,23 In contrast and admittedly in a slightly diﬀerent
context, drug eluting stents, for example, beneﬁting hundreds
of thousands of recipients globally, have been much more
easily analyzed to provide the necessary statistical numbers24,25
with good prospects for return of investment to companies.
Collectively, these factors have caused a formidable hurdle
that has largely precluded translation of antimicrobial
combination implants and devices from bench to bedside.
■ PREVENTIVE OR THERAPEUTIC GOALS OF A
COMBINATION DEVICE
In academic research, the distinction between preventive and
therapeutic goals of perceived innovations with respect to the
control of implant or device infections is not always made
clear. In a therapeutic approach, a matured bioﬁlm community
with all its well-known recalcitrance features to treatment
needs to be eradicated, which is much more diﬃcult than the
killing of peri-operatively introduced bacteria adhering as
individuals on an implant or device surface, required to prevent
development of infection.16 Herewith, distinction between
preventive and therapeutic goals forms the key to success in
the development of many antimicrobial implant and device
strategies. Generally, the preventive approach is for device
companies a more interesting one. However, preventive claims
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would, under the current regulatory requirements, necessitate
either an immense clinical trial enrollment to provide suﬃcient
power to delineate the small fraction of patients actually
beneﬁting from antimicrobial implants, or patient stratiﬁcation
and triage to streamline trial cohorts for preventive treatment
based on identiﬁable infection risk factors. Yet, also from a
patients perspective, preventive goals are clearly preferable
above therapeutic ones.
■ RECOMMENDATIONS TO FACILITATE
DOWNWARD CLINICAL TRANSLATION
Seeking to relieve the factors that stagnate downward clinical
translation and availability of antimicrobial combination
implants and devices that prevent or reduce the likelihood of
biomaterial-implant-associated infections, a change in dialogue
between the various key players involved in the current
translational blockade is required (see Figure 1). For
policymakers and regulatory agencies, this trans-Atlantic
consortium recommends that
(1) Clinical beneﬁt and eﬃcacy assessments performed in
high-risk patient groups for antimicrobial combination
implants and devices should be considered for
extrapolation to general patient populations without
necessarily requiring clinical demonstration of beneﬁt
(“enrichment-from-patient”).
Rationale: Clinical improvements can be demonstra-
ted with statistical signiﬁcance with a far lower number
of implant or device recipients enrolled in clinical trials
when carried out in high-risk patients (i.e., trauma
patients or patients suﬀering from diabetes) than when
carried out in “healthy” patients, often requiring
enrollment of tens or hundreds of thousands of patients.
However, regulatory agencies demand a control group
with infection rates similar to patients without
comorbidity, but the need for such a demand remains
unclear. We therefore recommend that clinical improve-
ments demonstrated in high-risk patient groups be
enriched to claims for the general patient population
requiring a speciﬁc implant or device.
(2) Clinical trials in less-developed countries with infection
rates higher than global averages for a certain device
should be accepted for beneﬁt demonstration of
antimicrobial combination implants and devices of the
same type (“enrichment-from-population”).
Rationale: Biomaterial implant and device manufac-
turers and academicians often seek sites in less-
developed countries to host clinical trials for antimicro-
bial beneﬁt demonstration, as they usually have higher
infection rates. In such trials, clinical improvements can
be demonstrated with statistical signiﬁcance without
reaching out to tens or hundreds of thousands of
patients required for a similar study within the United
States or Europe. However, regulatory agencies demand
a control group with infection rates similar to domestic
ones, but the need for such a requirement remains
unclear. We therefore recommend that clinical improve-
ments demonstrated in less-developed countries be
enriched to approved domestic claims in the absence
of other confounding factors aﬀecting outcomes (i.e.,
physiological, genomic, or anatomical diﬀerences,
clinical treatment or standard of care diﬀerences).
(3) In cases of an already-approved combination implant or
device with antimicrobial coating, replacement of that
coating with another coating or application to an
implant or device with diﬀerent designs or geometries
Figure 1. Key players involved in the current translational blockade that impedes clinical availability of new antimicrobial combination devices to
prevent biomaterial-associated infections, placing the patient against the will of each individual key player, trapped in a deadlock situation. Current
positions assumed by key players (blue italic text) and new dialogue content needed between diﬀerent key players (black italic text) to free the
patient from this position, as based on our recommendations, are both indicated.
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should not require the same type and extent of
regulatory assessment of risk/beneﬁt as for the already-
approved device (“enrichment-from-component”).
Rationale: An approved combination implant or
device equipped, for instance, with an antibiotic-
releasing coating is often modiﬁed in small steps to
meet new requirements stimulated, for instance, by the
development of new, antibiotic-resistant strains or
changes in geometry. In such cases, a change in
geometry or replacement of an already established and
implemented antibiotic by another one should be
approved by enrichment of an approved product without
the same type and extent of regulatory assessment.
Regulatory bodies are often blamed for the current
deadlocked translational situation, but regulatory bodies only
enforce rules deﬁned by policymakers (see also Figure 1). This
leads to our next recommendation on relevant policies,
addressing academicians and clinicians alike:
4. Academicians and clinicians should be more active in
advising policymakers about more realistic regulations
concerning new approvals of antimicrobial combination
implants and devices.
Rationale: Academicians and clinicians are the only
experts in the ﬁeld who can independently advise
policymakers on changes necessary in regulatory
requirements. Advising policymakers on more realistic
regulations should be done equally with professional
academic and clinical duties to modify current
regulations as a ﬁrst step to produce feasible regulatory
requirements to obtain approval for antimicrobial
combination implants and devices. The current trend
in academia that performance evaluation should go
beyond bibliometric analysis and include an outreach
portfolio (“what did I do, why does it matter”)26 may
constitute the stimulus for academic researchers and
clinicians to pick up this indispensable role to change
regulatory requirements.
These recommendations do not relieve medical device
manufacturers from their duties to demonstrate beneﬁt, for
which we propose the following:
5. Infection-resistant combination devices conditionally
approved on an enrichment basis should be mandatorily
enrolled in global registry studies supervised by
regulatory agencies for a minimum ﬁve-year period or
until statistically validated evidence for noninferiority or
superiority of claims is demonstrated.
Rationale: Clinical practice should be evidence-based.
In the absence of possibilities for prospective clinical
trials for the diverse reasons mentioned above,
retrospective clinical trials should be allowed to provide
the necessary evidence for noninferiority or superiority
of antimicrobial combination implants or devices
approved on an enrichment basis.
Finally, both healthcare payers and patients must realize that
the costs of bringing new antimicrobial combination implants
and devices to the market not only comprise substantive
research and development costs but also expenditures for
clinical trials to demonstrate human beneﬁt and patient safety.
Our consortium believes that implementation of the above-
cited recommendations will help to facilitate downward clinical
translation of new antimicrobial combination devices to the
market and therewith clinical use and patient beneﬁts. Our
recommendations, however, leave manufacturers uncertain
about the ultimate approval prospects for a new antimicrobial
device approved on an enrichment basis. This creates
uncertainty about ﬁnancial returns. Therefore, healthcare
payers and patients should express equal willingness to pay
for procedures using antimicrobial combination implants and
devices approved on an enrichment basis as when performed
with otherwise approved ones, even when possibly more
expensive.
These recommendations (summarized in Box 1) are
proposed with the intent of stimulating the needed dialogue
between academicians, clinicians, manufacturers, policymakers
and regulatory agencies, healthcare payers, and patients, as
these key-players all must act in unison to further advance this
ﬁeld on which much of the future of healthcare is based.
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Box 1. Key Concepts Box
• Biomaterial-implant-associated infections are causing
dramatic increases in patient morbidity and mortality
and ﬁnancial burden to health care payers, including
patients.
• Although numerous antimicrobial combination im-
plants and devices are reported annually in scientiﬁc
publications, the current regulatory landscape makes
clinical beneﬁt demonstration impossible, presenting a
blockade to their downward clinical translation.
• Healthcare payers, academicians and doctors, policy-
makers, regulatory agencies, manufacturers, and patients
should take their respective responsibilities to facilitate
more eﬃcient dialogue to create more realistic
regulations allowing clinical translation of antimicrobial
combination implants and devices.
• Regulatory approval of antimicrobial combination
implants and devices should be allowed based on
enrichment of claims from (1) high- to low-risk patient
groups, (2) from high- to low-risk population groups,
and (3) one to another component of the same device.
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